Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic Antibiotics for VAP Prevention
NCT07203638Enrolling by invitation
- Start
- Nov 2024
- Primary completion
- Nov 2025
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Randomised, double-blind trial of cefepime in ventilator-associated pneumonia (VAP) (2 arms). Primary endpoint: Ventilation associated pneumonia. Started Nov 2024; status: enrolling by invitation.
02
Drugs
cefepime
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT07203638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07203638.